According to a new pan-cancer meta-examination of nearly 18,000 gene expression signatures, FOXM1 is recognized as a significant predictor of detrimental outcomes in 39 hematologic and solid malignancies, including MM. This evidence concerns the gene FOXM1 and Miyoshi myopathy.